29 related articles for article (PubMed ID: 9332769)
1. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.
Boiko IV; Mitchell MF; Hu W; Pandey DK; Mathevet P; Malpica A; Hittelman WN
Clin Cancer Res; 1998 Jun; 4(6):1383-91. PubMed ID: 9626454
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
[TBL] [Abstract][Full Text] [Related]
3. Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine.
Poulin N; Boiko I; MacAulay C; Boone C; Nishioka K; Hittelman W; Mitchell MF
Cytometry; 1999 Oct; 38(5):214-23. PubMed ID: 10516607
[TBL] [Abstract][Full Text] [Related]
4. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.
Bacus JW; Boone CW; Bacus JV; Follen M; Kelloff GJ; Kagan V; Lippman SM
Cancer Epidemiol Biomarkers Prev; 1999 Dec; 8(12):1087-94. PubMed ID: 10613341
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3.
Vlastos AT; West LA; Atkinson EN; Boiko I; Malpica A; Hong WK; Follen M
Clin Cancer Res; 2005 Jan; 11(1):390-6. PubMed ID: 15671570
[TBL] [Abstract][Full Text] [Related]
6. DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia.
Boiko IV; Mitchell MF; Pandey DK; White RA; Hu W; Malpica A; Nishioka K; Boone CW; Atkinson EN; Hittelman WN
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):849-55. PubMed ID: 9332769
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic use of DNA image cytometry in cervical squamous intraepithelial lesions and invasive carcinoma.
Böcking A; Nguyen VQ
Cancer; 2004 Feb; 102(1):41-54. PubMed ID: 14968417
[TBL] [Abstract][Full Text] [Related]
9. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
10. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Grabosch SM; Shariff OM; Helm CW
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD004121. PubMed ID: 29431861
[TBL] [Abstract][Full Text] [Related]
12. Retinoids for preventing the progression of cervical intra-epithelial neoplasia.
Helm CW; Lorenz DJ; Meyer NJ; Rising WR; Wulff JL
Cochrane Database Syst Rev; 2007 Oct; (4):CD003296. PubMed ID: 17943787
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
